Treatment of stroke using isolated placental cells
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-063/00
A61K-035/50
C12N-005/073
A61K-035/12
출원번호
US-0545029
(2009-08-20)
등록번호
US-8828376
(2014-09-09)
발명자
/ 주소
Zeitlin, Andy
Pal, Ajai
출원인 / 주소
Anthrogenesis Corporation
대리인 / 주소
Jones Day
인용정보
피인용 횟수 :
0인용 특허 :
148
초록
Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and/or compositions comprising placental stem cells.
대표청구항▼
1. A method of treating an individual having a disruption in the flow of blood in or around the brain, comprising administering to said individual an effective amount of an isolated population of cells comprising human adherent placental cells that are CD10+, CD34−, CD105+, and CD200+, wherein at le
1. A method of treating an individual having a disruption in the flow of blood in or around the brain, comprising administering to said individual an effective amount of an isolated population of cells comprising human adherent placental cells that are CD10+, CD34−, CD105+, and CD200+, wherein at least 70% of said placental cells in said population of cells are non-maternal in origin. 2. The method of claim 1, wherein said therapeutically effective amount is an amount that results in elimination of a detectable improvement in, lessening of the severity of, or slowing of the progression of one or more symptoms of disruption in the flow of blood in or around the brain exhibited by said individual. 3. The method of claim 2, wherein said symptom is hemiplegia or hemiparesis. 4. The method of claim 2, wherein said symptom is muscle weakness of the face; numbness; reduction in sensation; altered smell, taste, hearing, or vision; loss of smell, taste, hearing, or vision; drooping of an eyelid (ptosis); detectable weakness of an ocular muscle; decreased gag reflex; decreased ability to swallow; decreased pupil reactivity to light; decreased sensation of the face; decreased balance; nystagmus; altered breathing rate; altered heart rate; weakness in sternocleidomastoid muscle with decreased ability or inability to turn the head to one side; weakness in the tongue; aphasia (inability to speak or understand language); apraxia (altered voluntary movements); a visual field defect; a memory deficit; hemineglect or hemispatial neglect (deficit in attention to the space on the side of the visual field opposite the lesion); disorganized thinking; confusion; development of hypersexual gestures; anosognosia (persistent denial of the existence of a deficit); difficulty walking; altered movement coordination; vertigo; disequilibrium; loss of consciousness; headache; or vomiting, wherein said symptom is caused by disruption in the flow of blood in or around the brain. 5. The method of claim 1, wherein at least 80% of the cells in said population are said isolated human adherent placental cells. 6. The method of claim 1, wherein at least 90% of the cells in said population are said isolated human adherent placental cells. 7. The method of claim 1, wherein said disruption of the flow of blood is stroke. 8. The method of claim 7, wherein said stroke is ischemic stroke. 9. The method of claim 7, wherein said stroke is hemorrhagic stroke. 10. The method of claim 1, wherein said disruption is a hematoma. 11. The method of claim 10, wherein said hematoma is a dural hematoma, a subdural hematoma, or a subarachnoid hematoma. 12. The method of claim 1, wherein said disruption is vasospasm. 13. The method of claim 1, wherein said population of cells is administered by bolus injection. 14. The method of claim 1, wherein said population of cells is administered by intravenous infusion. 15. The method of claim 1, wherein said population of cells is administered intracranially. 16. The method of claim 15, wherein said population of cells is administered within an area of ischemia. 17. The method of claim 15, wherein said population of cells is administered to an area peripheral to an ischemia. 18. The method of claim 1, wherein said population of cells is administered intraperitoneally, intramuscularly, intradermally or intraocularly. 19. The method of claim 1, wherein said population of cells is administered by surgical implantation of a composition comprising said population of cells. 20. The method of claim 19, wherein said composition is a matrix or scaffold. 21. The method of claim 20, wherein said matrix or scaffold is a hydrogel. 22. The method of claim 20, wherein said matrix or scaffold is a decellularized tissue. 23. The method of claim 20, wherein said matrix or scaffold is a synthetic biodegradable composition. 24. The method of claim 1, wherein said population of cells is administered once to said individual. 25. The method of claim 1, wherein said population of cells is administered to said individual a plurality of times. 26. The method of claim 1, wherein said administering comprises administering a population of cells comprising between about 1×104 and 1×105 isolated placental cells per kilogram of said individual. 27. The method of claim 1, wherein said administering comprises administering a population of cells comprising between about 1×105 and 1×106 isolated placental cells per kilogram of said individual. 28. The method of claim 1, wherein said administering comprises administering a population of cells comprising between about 1×106 and 1×107 isolated placental cells per kilogram of said individual. 29. The method of claim 1, wherein said administering comprises administering a population of cells comprising between about 1×107 and 1×108 isolated placental cells per kilogram of said individual. 30. The method of claim 1, wherein said administering comprises administering a population of cells comprising between about 5×107 and 3×109 isolated placental cells intravenously. 31. The method of claim 30, wherein said administering comprises administering a population of cells comprising about 9×108 isolated placental cells. 32. The method of claim 30, wherein said administering comprises administering a population of cells comprising about 1.8×109 isolated placental cells. 33. The method of claim 1, wherein said administering comprises administering a population of cells comprising between about 5×107 and 1×108 isolated placental cells intracranially. 34. The method of claim 33, wherein said administering comprises administering a population of cells comprising about 9×107 isolated placental cells. 35. The method of claim 1, comprising administering a second therapeutic agent to said individual. 36. The method of claim 35, wherein said second therapeutic agent is a neuroprotective agent. 37. The method of claim 36, wherein said second therapeutic agent is NXY-059 (disuifonyl derivative of phenylbutylnitrone). 38. The method of claim 35, wherein said second therapeutic agent is a thrombolytic agent. 39. The method of claim 38, wherein said thrombolytic agent is tissue plasminogen activator (tPA). 40. The method of claim 1, wherein said population of cells is administered to said individual within 48 hours of development of one or more symptoms of disruption of blood How in or around the brain in said individual. 41. The method of claim 1, wherein said population of cells is administered to said individual within 24 hours of development of one or more symptoms of disruption of blood flow in or around the brain in said individual. 42. The method of claim 1, wherein said population of cells is administered to said individual within 12 hours of development of one or more symptoms of disruption of blood flow in or around the brain in said individual. 43. The method of claim 1, wherein said population of cells is administered to said individual within 3 hours of development of one or more symptoms of disruption of blood flow in or around the brain in said individual. 44. The method of claim 1, wherein said isolated placental cells in said population were cryopreserved prior to said administering. 45. The method of claim 1, wherein said isolated human adherent placental cells in said population are obtained from a placental stem cell bank.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (148)
Pittenger Mark F., Adipogenic differentiation of human mesenchymal stem cells.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Compositions containing cultured mitotic human stem cells.
Caplan Arnold I. ; Haynesworth Stephen E. ; Gerson Stanton L. ; Lazarus Hillard M., Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells.
Bauer S. Christopher ; Abrams Mark Allen ; Braford-Goldberg Sarah Ruth ; Caparon Maire Helena ; Easton Alan Michael ; Klein Barbara Kure ; McKearn John Patrick ; Olins Peter O. ; Paik Kumnan ; Thomas, Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines.
Bjornson Christopher R. ; Rietze Rod L.,AUX ; Reynolds Brent A.,CAX ; Vescovi Angelo L.,ITX, Generation of hematopoietic cells from multipotent neural stem cells.
Nakahata Tatsutoshi (Matsumoto JPX) Kawano Genji (Kamakura JPX) Sudo Tetsuo (Kamakura JPX) Kojima Katsuaki (Yokohama JPX), Hematopoietic stem cell growth-promoting compositions containing a fibroblast-derived fragment of fibronectin and a grow.
Rubinstein Pablo ; Coelho Philip Henry ; Stevens Cladd E., High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjuncti.
Janice M. Davis-Sproul ; Mark Aaron Moorman ; Renee Marie McNeil ; Donald William Simonetti, Jr. ; Lora Catherine Hammill ; Stewart Craig, Human mesenchymal stem cells.
Srour Edward (Indianapolis IN) Zanjani Esmail (Reno NV) Brandt John E. (Indianapolis IN) Hoffman Ronald (Indianapolis IN), Human stem cell compositions and methods.
Tsukamoto Ann (Palo Alto CA) Baum Charles M. (Mountain View CA) Aihara Yukoh (Yokohama JPX) Weissman Irving (Palo Alto CA), Identification and isolation of human hematopoietic stem cells.
Prockop Darwin J. ; Pereira Ruth F. ; Leeper Dennis B. ; O'Hara Michael D., Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects.
Edward A. Boyse ; Hal E. Broxmeyer ; Gordon W. Douglas, Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
Boyse Edward A. (Tucson AZ) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of the.
Kevin R. McIntosh ; Joseph D. Mosca ; Elena N. Klyushnenkova, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh Kevin R. ; Mosca Joseph D. ; Klyushnenkova Elena N., Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh, Kevin R.; Mosca, Joseph D.; Klyushnenkova, Elena, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultur.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for treating connective tissue disorders.
Murray Lesley (San Jose CA) Sutherland D. Robert (Oakville CAX), Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby an.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI) Schwartz Richard M. (Ann Arbor MI), Methods and compositions for the ex vivo replication of human hematopoietic stem cells.
Emerson Stephen G. ; Clarke Michael F. ; Palsson Bernhard O., Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 sec.
Terstappen, Leon W. M. M.; Rao, Galla Chandra; Uhr, Jonathan W.; Racila, Emilian V.; Liberti, Paul A., Methods and reagents for the rapid and efficient isolation of circulating cancer cells.
Anderson David J. ; Shah Nirao M., Methods for differentiating neural stem cells to neurons or smooth muscle cells using TGT-.beta. super family growth factors.
Csete Marie ; Doyle John ; Wold Barbara, Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells.
Palsson Bernhard O. (Ann Arbor MI) Armstrong R. Douglas (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Emerson Stephen G. (Ann Arbor MI), Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods for the ex vivo replication of human stem cells and/or expansion of human progenitor cells.
Hill Beth Louise ; Rozler Elen ; Chen Benjamin P., Methods of obtaining compositions enriched for hematopoietic stem cells, antibodies for use therein, compositions derived therefrom and methods of use thereof.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods, compositions and devices for growing human hematopoietic cells.
Palsson Bernhard O. ; Emerson Stephen G. ; Schwartz Richard M., Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells.
Hariri,Robert J.; Stirling,David I.; Moutouh De Parseval,Laure A.; Chan,Kyle W. H., Modulation of stem and progenitor cell differentiation, assays, and uses thereof.
Vyakarnam Murty N. ; Zimmerman Mark C. ; Scopelianos Angelo George ; Roller Mark B. ; Gorky David V., Porous tissue scaffoldings for the repair of regeneration of tissue.
Vyakarnam, Murty N.; Zimmerman, Mark C.; Scopelianos, Angelo George; Roller, Mark B.; Gorky, David V., Porous tissue scaffoldings for the repair or regeneration of tissue.
Boyse Edward A. (New York NY) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
McIntosh, Kevin; Klyushnenkova, Elena, Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation.
Gerson Stanton L. (Pepper Pike OH) Caplan Arnold I. (Cleveland Heights OH) Haynesworth Stephen E. (Cleveland Heights OH), Transduced mesenchymal stem cells.
Hessel Stephen R. (Fountain Valley CA) Young H. Theodore (Lake Forest CA) Katz Michael (Richmond CA), Umbilical cord clamping, cutting, and blood collecting device and method.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.